Background {#sec1_1}
==========

Worldwide diabetic macular edema (DME) is reported to have a prevalence of 6.8% and results in vision loss \[[@B1]\]. DME management can be difficult, with only around 15% of the patients achieving significant vision recovery with laser, the current standard of care \[[@B2]\]. A number of pharmacotherapies are now licensed for the treatment of DME in Europe, including anti-vascular endothelial growth factor agents and corticosteroid therapies \[[@B3]\], which are used to target vascular endothelial growth pathways and inflammatory pathways, respectively.

In diabetes, there is increased expression of leukocyte adhesion molecules on the endothelial cell walls. Leukocytes release free radicals and enzymes that cause direct damage to endothelial cells, increasing blood retinal barrier leakage. They also release cytokines, including vascular endothelial growth factor, tumor necrosis factor-α, and interleukin-6, which act through various signaling pathways to increase vascular permeability \[[@B4]\].

Corticosteroids are known anti-inflammatory and angiostatic agents. Inhibiting the release of cytokines with a corticosteroid -- such as dexamethasone, triamcinolone or fluocinolone -- has been shown to reduce DME and rehabilitate vision in several pivotal clinical studies \[[@B3]\]. ILUVIEN contains the corticosteroid fluocinolone acetonide (FAc) and uses microdosingTM technology to release FAc at a daily rate of 0.2 μg for up to 3 years \[[@B5]\]. This differs significantly from both the dexamethasone delivery system and that of triamcinolone, which are reported to have a duration of action of only up to 3 and 4 months, respectively \[[@B6]\]. The effectiveness of ILUVIEN was demonstrated in the FAME trials (NCT00344968) in which patients with DME who had previously shown an insufficient response to laser were treated with either a 0.2 μg/day (ILUVIEN) or 0.5 μg/day FAc implant and were compared against a sham-control treated population. Both FAME trials independently met their primary endpoint and showed that significantly more patients with chronic DME treated with the 0.2 μg/day FAc implant experienced a ≥15-letter improvement in visual acuity (VA) at month 24 than sham-control patients (pooled data; 34.4 vs. 13.4%; *p* \< 0.001) and that this benefit was sustained to month 36. Functional improvements were accompanied by rapid and sustained improvements in central foveal thickness (CFT) \[[@B5]\].

In Europe, ILUVIEN was first licensed in 2012. ILUVIEN is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema considered insufficiently responsive to available therapies. Since then, its usage in real-life clinical practice has steadily been increasing. Miss Clare Bailey presented the real world outcomes from a UK audit of patients treated with ILUVIEN at the annual meeting of the Royal College of Ophthalmologists in Birmingham, UK, between June 24 and 26, 2016. This unpublished interim analysis showed that the majority of treated eyes (≥69.4% of 290 eyes) maintained or improved VA. To date, however, relatively limited data with a longer-term follow-up of the functional and structural responses following treatment with ILUVIEN have been reported. The case described herein provides data for both VA and CFT over a 24-month follow-up period.

Case Presentation {#sec1_2}
=================

A 68-year-old Caucasian female with type 2 diabetes mellitus had diffuse DME diagnosed in her left eye in October 2010. The treatment history is summarised in Table [1](#T1){ref-type="table"} and was previously reported when only 6 months of follow-up were available. At diagnosis, VA was 46 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, converted from Snellen VA using the equation 85 + 50 x log (Snellen fraction), CFT was 712 microns, and intraocular pressure (IOP) was ≤22 mm Hg.

The patient had phacoemulsification plus intraocular lens insertion in the left eye in February 2012. Intravitreal triamcinolone acetonide was also administered to treat the persistent DME postoperatively. At the first postoperative visit, VA was 70 ETDRS letters, CFT was 278 microns, and IOP was 20 mm Hg. Over the next 5 months, VA (50 ETDRS letters) and CFT (805 microns) progressively worsened, and the patient was admitted into the Matisse trial in September 2012 to test the effects of ranibizumab plus a small-interfering RNA agent.

Between October 2012 and March 2014, the patient received 5 injections of ranibizumab plus the small-interfering RNA agent and then subsequently listed for 2 further courses of 3 intravitreal injections of ranibizumab. By the end of this stage of treatment, by 1 month after the final injection of ranibizumab, the DME had recurred, VA was 55 ETDRS letters, CFT was 774 microns, and IOP was 17 mm Hg.

The patient\'s DME was now chronic (over 18 months of duration), relapsing, and her CRT had fluctuated wildly through the different treatment phases, which is believed to have a deleterious effect on the function of the retina and, more specifically, on the visual function due to the presence of submacular fluid \[[@B7]\]. It was at this stage that the patient was treated with ILUVIEN according to NICE TA301 (please see <http://www.nice.org.uk/guidance/ta301/chapter/1-Guidance>). Figure [1](#F1){ref-type="fig"} shows the response of VA and CFT after a single ILUVIEN implant without any further treatment to this eye over the next 2 years. Within 7 days, VA had increased to 61 ETDRS letters and CFT had decreased to 267 microns. Within 2 weeks, VA had improved further to 70 ETDRS letters, which is the legal requirement to hold a driving license in the UK. These early improvements were then largely maintained throughout the next 24 months without further intervention, as shown in Figure [1](#F1){ref-type="fig"}. Figure [2](#F2){ref-type="fig"} shows optical coherence tomography scans before and after ILUVIEN implantation, illustrating the structural improvement that occurred alongside the functional improvement in vision. Over the course of the 2-year period, IOP remained below 21 mm Hg, and no IOP-lowering medication was required.

Conclusion {#sec1_3}
==========

This is the first case that the authors are aware of, which shows that a single injection of the 0.2 μg/day FAc implant leads to rapid improvements (within 7 days) in VA and CFT that are maintained over 2 years of follow-up. This was despite 11 previous injections of ranibizumab, which failed to control the DME prior to treatment with ILUVIEN. The functional and structural responses presented herein are consistent with those reported in the FAME trials, with rapid and marked responses observed early and being sustained in the long term. This patient will continue to be monitored to see if the responses reported in controlled clinical trials are replicated with a single injection in real-life UK practice over a 36-month period.
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![The change in central foveal thickness (top panel) and visual acuity (bottom panel) following intravitreal injection of ILUVIEN.](cop-0007-0301-g01){#F1}

![Optical coherence tomography scan showing the foveal thickness prior to (**a**; March 2011) and 2 years after intravitreal ILUVIEN (**b**; April 2016) in the left eye.](cop-0007-0301-g02){#F2}

###### 

Treatment history of the left eye

  Date         Number of days between visits   Description                                                                                VA     ETDRS letters   CFT, microns
  ------------ ------------------------------- ------------------------------------------------------------------------------------------ ------ --------------- --------------
  13/07/2009   224                             Proliferative retinopathy diagnosed                                                        NN     NN              NN
  14/08/2009   32                              Panretinal laser photocoagulation                                                          6/6    85              NN
  21/10/2009   68                              Quiecscent laser-treated retinopathy                                                       6/6    85              NN
  20/10/2010   364                             Diffuse DME diagnosed                                                                      6/36   46              712
  19/11/2010   30                              IVTA injection                                                                             NN     NN              NN
  14/12/2010   25                              Underwent macular grid                                                                     6/18   61              304
  25/01/2011   42                              Visit                                                                                      6/18   61              283
  02/03/2011   36                              Visit                                                                                      6/12   70              279
  18/01/2012   322                             Dense cataract                                                                             6/36   46              612
  02/02/2012   15                              Phacoemulsification; +IOL; IVTA to treat cataract and recurrent DME                        NN     NN              NN
  16/04/2012   74                              Visit                                                                                      6/12   70              278
  31/08/2012   137                             Visit                                                                                      6/36   46              769
  24/09/2012   24                              Visit; admitted into the Matisse trial (ranibizumab + siRNA agent)                         6/30   50              805
  08/10/2012   14                              1st study injection                                                                        NN     NN              NN
  12/11/2012   35                              2nd study injection                                                                        6/15   65              352
  10/12/2012   28                              3rd study injection                                                                        6/12   70              279
  07/01/2013   28                              4th study injection                                                                        6/9    76              271
  04/02/2013   28                              5th study injection                                                                        6/9    76              304
  04/03/2013   28                              Visit                                                                                      6/9    76              332
  08/04/2013   35                              Patient exits study listed for ranibizumab injection due to residual and progressive DME   6/12   70              577
  06/06/2013   59                              Ranibizumab injection                                                                      NN     NN              NN
  09/07/2013   33                              Ranibizumab injection                                                                      NN     NN              NN
  23/08/2013   45                              Ranibizumab injection                                                                      NN     NN              NN
  07/09/2013   15                              Visit                                                                                      6/36   46              451
  17/10/2013   40                              Ranibizumab injection                                                                      NN     NN              NN
  21/11/2013   35                              Ranibizumab injection                                                                      NN     NN              NN
  10/01/2014   50                              Ranibizumab injection                                                                      NN     NN              NN
  03/03/2014   52                              Visit                                                                                      6/24   55              774
  21/03/2014   18                              ILUVIEN injection                                                                          NN     NN              NN
  28/03/2014   7                               Visit                                                                                      6/18   61              267
  04/04/2014   7                               Visit                                                                                      6/12   70              241
  06/06/2014   63                              Visit                                                                                      6/12   70              234
  04/09/2014   90                              Visit                                                                                      6/12   70              245
  30/09/2014   26                              Visit                                                                                      6/18   61              245
  01/02/2015   124                             Visit                                                                                      6/12   70              239
  28/03/2015   55                              Visit                                                                                      6/18   61              240
  08/05/2015   41                              Visit                                                                                      6/6    85              251
  25/09/2015   140                             Visit                                                                                      6/9    76              252
  24/10/2015   29                              Visit                                                                                      6/18   61              NN
  28/01/2016   96                              Visit                                                                                      6/12   70              250
  02/03/2016   34                              Visit                                                                                      6/12   70              NN
  06/04/2016   94                              Visit                                                                                      6/12   70              250

VA, visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; CFT, central foveal thickness; IVTA, intravitreal triamcinolone acetonide; NN, no numbers; IOL, intraocular lens; siRNA, small-interfering RNA; DME, diabetic macular oedema.
